B. Bernstein

发表

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

J. Mellors, D. Kempf, J. Coffin, 2008, Proceedings of the National Academy of Sciences.

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.

Thomas Berg, Stefan Zeuzem, Xavier Forns, 2014, The New England journal of medicine.

Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Stefan Zeuzem, Junyuan Xiong, Edward Tam, 2014, The New England journal of medicine.

Pharmacokinetics and Safety of the Lopinavir/Ritonavir Tablet 500/125 mg Twice Daily Coadministered With Efavirenz in Healthy Adult Participants

Y. Chiu, B. Bernstein, C. Klein, 2012, Journal of clinical pharmacology.

HCV RNA Assay Sensitivity Impacts the Management of Patients Treated with Direct-Acting Antivirals

J. Pawlotsky, C. Sarrazin, H. Wedemeyer, 2015, Antiviral therapy.

Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy.

J. Pawlotsky, C. Sarrazin, H. Wedemeyer, 2015, Journal of virological methods.

1229 GENOTYPIC AND PHENOTYPIC CHARACTERIZATION OF NS3 VARIANTS SELECTED IN HCV-INFECTED PATIENTS TREATED WITH ABT-450

T. Pilot‐Matias, B. Bernstein, C. Collins, 2011 .

1399 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R +ABT-333 +RIBAVIRIN ACHIEVED SVR12 IN MORE THAN 90% OF TREATMENT-NAIVE HCV GENOTYPE-1-INFECTED SUBJECTS AND 47% OF PREVIOUS NON-RESPONDERS

G. Everson, K. Kowdley, E. Lawitz, 2012 .

Loss of Bone Mineral Density After Antiretroviral Therapy Initiation, Independent of Antiretroviral Regimen

M. King, T. Brown, G. McComsey, 2009, Journal of acquired immune deficiency syndromes.

Exploratory study of oral combination antiviral therapy for hepatitis C.

T. Pilot‐Matias, K. Kowdley, D. Cohen, 2013, The New England journal of medicine.

Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.

T. Pilot‐Matias, G. Everson, P. Kwo, 2014, The New England journal of medicine.

Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment.

S. Dutta, T. Marbury, E. Lawitz, 2015, Journal of hepatology.

Factors associated with severity of depression and high-risk sexual behavior among persons diagnosed with human immunodeficiency virus (HIV) infection.

J. S. St. Lawrence, L. Y. Stevenson, T. Brasfield, 1993, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.

M. King, S. Brun, J. Arribas, 2008, The Journal of infectious diseases.

1210 ABT-267 COMBINED WITH PEGYLATED INTERFERON ALPHA-2A/RIBAVIRIN IN GENOTYPE 1 (GT1) HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12 WEEK ANTIVIRAL AND SAFETY ANALYSIS

T. Pilot‐Matias, W. Xie, E. Lawitz, 2012 .

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

G. Beall, M. Johnson, M. King, 2002, The New England journal of medicine.

1187 ABT-450/RITONAVIR (ABT-450/R) COMBINED WITH PEGYLATED INTERFERON ALPHA-2A/RIBAVIRIN AFTER 3-DAY MONOTHERAPY IN GENOTYPE 1 (GT1) HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12-WEEK SUSTAINED VIROLOGIC RESPONSE (SVR12) AND SAFETY RESULTS

T. Pilot‐Matias, K. Kowdley, W. Xie, 2012 .

Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial.

M. King, M. Witt, H. Kessler, 2004, The Journal of infectious diseases.

Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates from Protease Inhibitor-Experienced Patients

Richard A. Rode, Dale J. Kempf, D. Kempf, 2001, Journal of Virology.

The effect of food on ritonavir bioavailability following administration of ritonavir 100 mg film-coated tablet in healthy adult subjects

B. Bernstein, T. Podsadecki, C. Klein, 2008 .

Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children

O. Ramilo, A. Hsu, D. Kempf, 2003, The Pediatric infectious disease journal.

Pharmacokinetics and Dose Recommendations for Cyclosporine and Tacrolimus When Coadministered With ABT‐450, Ombitasvir, and Dasabuvir

S. Dutta, E. Coakley, D. Cohen, 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Eoin Coakley, Junyuan Xiong, Jordan J Feld, 2014, The New England journal of medicine.

13 A 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R, ABT-072, AND RIBAVIRIN WAS WELL TOLERATED AND ACHIEVED SUSTAINED VIROLOGIC RESPONSE IN 91% TREATMENT-NAIVE HCV IL28B-CC GENOTYPE-1-INFECTED SUBJECTS

K. Kowdley, D. Cohen, E. Lawitz, 2012 .

A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1.

T. Pilot‐Matias, K. Kowdley, D. Cohen, 2013, Journal of hepatology.

Didanosine Compared with Continuation of Zidovudine in HIV-infected Patients with Signs of Clinical Deterioration While Receiving Zidovudine

A. Cross, D. Peterson, I. Frank, 1994, Annals of Internal Medicine.

Pharmacokinetic-Pharmacodynamic Analysis of Lopinavir-Ritonavir in Combination with Efavirenz and Two Nucleoside Reverse Transcriptase Inhibitors in Extensively Pretreated Human Immunodeficiency Virus-Infected Patients

A. Hsu, G. Granneman, D. Kempf, 2003, Antimicrobial Agents and Chemotherapy.

Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.

M. King, B. Bernstein, G. Hanna, 2007, The Journal of antimicrobial chemotherapy.

In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 2 with Decreased Susceptibility to Lopinavir

F. Gao, A. Molla, D. Kempf, 2007, Antimicrobial Agents and Chemotherapy.

In Vitro Selection and Characterization of Human Immunodeﬁciency Virus Type 2 with Decreased Susceptibility to Lopinavir (cid:1)

A. Molla, D. Kempf, H. Mo, 2007 .

Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.

A. Hsu, D. Kempf, M. King, 2004, The Journal of infectious diseases.

Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized trial M05-730.

M. Johnson, D. Cohen, B. Bernstein, 2010, AIDS research and human retroviruses.

A Once-Daily Lopinavir/Ritonavir-Based Regimen Is Noninferior to Twice-Daily Dosing and Results in Similar Safety and Tolerability in Antiretroviral-Naive Subjects Through 48 Weeks

D. Podzamczer, M. Loutfy, S. Gibbs, 2009, Journal of acquired immune deficiency syndromes.

Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients.

J. Montaner, M. King, S. Brun, 2004, The Journal of infectious diseases.

ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.

O. Weiland, P. Ferenci, B. Müllhaupt, 2014, Gastroenterology.

Longitudinal evaluation of adrenocortical function in patients infected with the human immunodeficiency virus.

H. Raff, J. Findling, B. Bernstein, 1994, The Journal of clinical endocrinology and metabolism.

Analysis of the Virological Response with Respect to Baseline Viral Phenotype and Genotype in Protease Inhibitor-Experienced HIV-1-Infected Patients Receiving Lopinavir/Ritonavir Therapy

D. Kempf, M. King, S. Brun, 2001, Antiviral therapy.

Outcome of cognitive-behavioral and support group brief therapies for depressed, HIV-infected persons.

L. Y. Stevenson, T. Brasfield, S. Kalichman, 1993, The American journal of psychiatry.

3 SAFETY AND EFFICACY OF INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333 +/− RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GT1 INFECTION: RESULTS FROM THE AVIATOR STUDY

G. Everson, P. Kwo, K. Kowdley, 2013 .

High-Dose Lopinavir/Ritonavir in Highly Treatment-Experienced HIV-1 Patients: Efficacy, Safety, and Predictors of Response

D. Podzamczer, C. Katlama, D. Havlir, 2007, HIV clinical trials.

Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine.

B. Gazzard, M. King, C. Hicks, 2009, AIDS research and human retroviruses.

B. Bernstein, J. Gathe, T. Podsadecki, 2010, Journal of acquired immune deficiency syndromes.

1190 STUDY OF ABT-267 2-DAY MONOTHERAPY FOLLOWED BY 12-WEEK COMBINATION THERAPY IN TREATMENT-NAÏVE PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION

M. Epstein, T. Pilot‐Matias, T. Marbury, 2013 .

1186 SAFETY AND ANTIVIRAL ACTIVITY OF ABT-267, A NOVEL NS5A INHIBITOR, DURING 3-DAY MONOTHERAPY: FIRST STUDY IN HCV GENOTYPE-1 (GT1)-INFECTED TREATMENT-NAIVE SUBJECTS

T. Pilot‐Matias, T. Marbury, W. Xie, 2012 .

Geographic and Temporal Trends of Transmitted HIV-1 Drug Resistance Among Antiretroviral-Naïve Subjects Screening for Two Clinical Trials in North America and Western Europe

M. King, B. Bernstein, S. Rahim, 2009, HIV clinical trials.

1206 ABT-072 OR ABT-333 COMBINED WITH PEGYLATED INTERFERON/RIBAVIRIN AFTER 3-DAY MONOTHERAPY IN HCV GENOTYPE 1 (GT1)-INFECTED TREATMENT-NAIVE SUBJECTS: 12-WEEK SUSTAINED VIROLOGIC RESPONSE (SVR12) AND SAFETY RESULTS

T. Pilot‐Matias, K. Kowdley, W. Xie, 2012 .

Genotypic Correlates of Reduced In Vitro Susceptibility to ABT-378 in HIV Isolates From Patients Failing Protease Inhibitor Therapy

K. Hertogs, B. Larder, D. Kempf, 1999 .

Assessment of the bioequivalence and food effects for liquid and soft elastic capsule co-formulations of ABT-378/ritonavir in healthy subjects

A. Hsu, R. Bertz, B. Bernstein, 2000 .

Comparable Safety and Effi cacy With Once-daily (QD) Versus Twice-daily (BID) Dosing of Lopinavir/ritonavir (LPV/r) Tablets With Emtricitabine (FTC) + Tenofovir DF (TDF) in Antiretroviral (ARV)-naïve, HIV-1-infected Subjects: 96-Week Results of the Randomized Trial M05-730

M. Johnson, D. Cohen, B. Bernstein, 2009 .